S&P Futures
3,836.75-5.75(-0.15%)Dow Futures
30,766.00-76.00(-0.25%)Nasdaq Futures
13,548.50+63.00(+0.47%)
Grifols, S.A. (GRF.MC)
- Zacks
Aurinia (AUPH) Gets FDA Nod for Kidney Disorder Drug Lupkynis
Aurinia (AUPH) gets approval from the FDA for Lupkynis as a treatment for active lupus nephritis, a disease that causes irreversible kidney damage.
- Moody's
Grifols World Wide Operations USA, Inc. -- Moody's announces completion of a periodic review of ratings of Grifols S.A.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Grifols S.A. Paris, January 22, 2021 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Grifols S.A. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review discussion held on 13 January 2021 in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
- Zacks
Grifols (GRFS) to Begin Study on Plasma-Derived COVID-19 Drug
Grifols (GRFS) to begin a study in Spain to evaluate a plasma-derived medicine that would provide immediate immunity against COVID-19.
